ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.65
-0.26%
US Tech 100
19,168.00
0.52%
S&P 500
5,431.60
-0.04%
US Dollar vs CAD
1.3742
-0.07%
Bitcoin
66,454.51
-0.28%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Cel Sci Corporation New (CVM)

  7. Cel Sci Corporation New (CVM) News

CVM

Cel Sci (CVM)

Cel Sci Corporation New
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CVM
DateTimeSourceHeadlineSymbolCompany
06/06/20246:00AMBusiness WireDr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical AdvisorAMEX:CVMCel Sci Corporation New
05/16/20248:00AMBusiness WireCEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial ResultsAMEX:CVMCel Sci Corporation New
05/15/20243:17PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:CVMCel Sci Corporation New
05/10/20248:04AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
05/09/202412:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
05/09/20248:19AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
05/08/20248:00AMBusiness WireCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerAMEX:CVMCel Sci Corporation New
04/23/20248:00AMBusiness WireCEL-SCI Appoints Mario Gobbo to Its Board of DirectorsAMEX:CVMCel Sci Corporation New
03/19/20248:00AMBusiness WireCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyAMEX:CVMCel Sci Corporation New
03/07/202410:33AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:CVMCel Sci Corporation New
03/07/202410:33AMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersAMEX:CVMCel Sci Corporation New
03/07/202410:31AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:CVMCel Sci Corporation New
03/06/20247:45AMBusiness WireCEL-SCI Corporation Issues Letter to ShareholdersAMEX:CVMCel Sci Corporation New
02/15/20247:00AMBusiness WireCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsAMEX:CVMCel Sci Corporation New
02/14/20243:31PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:CVMCel Sci Corporation New
02/13/202411:00AMBusiness WireCEL-SCI Announces Closing of $7.75 Million Public Offering of Common StockAMEX:CVMCel Sci Corporation New
02/09/20247:44AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
02/09/20247:30AMBusiness WireCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common StockAMEX:CVMCel Sci Corporation New
02/06/20248:00AMBusiness WireCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugAMEX:CVMCel Sci Corporation New
01/31/20248:00AMBusiness WireEuropean Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®AMEX:CVMCel Sci Corporation New
01/02/20248:06AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
01/02/20248:03AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
01/02/20248:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:CVMCel Sci Corporation New
12/22/20233:01PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansAMEX:CVMCel Sci Corporation New
12/22/20237:00AMBusiness WireCEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate DevelopmentsAMEX:CVMCel Sci Corporation New
12/21/20233:15PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]AMEX:CVMCel Sci Corporation New
12/04/20237:30AMBusiness WireUK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck CancerAMEX:CVMCel Sci Corporation New
11/20/20234:25PMEdgar (US Regulatory)Form 8-K - Current reportAMEX:CVMCel Sci Corporation New
11/20/20233:15PMBusiness WireCEL-SCI Announces Closing of $5 Million Public Offering of Common StockAMEX:CVMCel Sci Corporation New
11/16/20237:39AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CVMCel Sci Corporation New
 Showing the most relevant articles for your search:AMEX:CVM

Your Recent History

USOTC
CNNA
Cann American (CE)
USOTC
HHSE
Hannover House (PK)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
ERHE
ERHC Energy (CE)
USOTC
RNVA
Rennova Health (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
AVXL
Anavex Life Sciences
NASDAQ
COOP
Mr Cooper
USOTC
CIVX
CTR Investments and Cons... (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
SMCE
SMC Entertainment (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
SPZI
Spooz (PK)
NASDAQ
DJT
Trump Media and Technology
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved